Balchem Corporation Reports Second Quarter 2025 Financial Results

About this update from Balchem Corporation

[{"type":"text","content":"MONTVALE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal second quarter ended June 30, 2025. For the quarter, the Company reported net sales of $255.5 million, net earnings of $38.3 million, adjusted EBITDA(a) of $69.2 million, and free cash flow(a) of $40.7 million. Ted Harris, Chairman, President and CEO of Balchem said, “The second quarter was another excellent quarter for Balchem. We delivered record financial results, driven by strong growth in all three of our reporting segments, while continuing to make good progress on our strategic growth initiatives.” Second Quarter 2025 Financial Highlights: Record net sales of $255.5 million, an increase of $21.4 million, or 9.1%, compared to the prior year quarter.GAAP net earnings were $38.3 million, an increase of 19.4%, from the prior year quarter.Record adjusted EBITDA was $69.2 million, an increase of 11.2%, from the prior year quarter.GAAP earnings per share of $1.17 compared to $0.98 in the prior year quarter and record adjusted earnings per share(a) of $1.27 compared to $1.09 in the prior year quarter.Cash flows from operations were $47.3 million, with free cash flow(a) of $40.7 million.Sales and earnings from operations growth in all three of our reporting segments with record sales and earnings from operations in Human Nutrition and Health and Specialty Products. Recent Highlights: Balchem announced its intent to build a new $36 million state-of-the-art food ingredient and nutraceutical micro-encapsulation manufacturing facility in Orange County, NY. If approved by the county, the facility will more than double Balchem's capacity for its fast-growing micro-encapsulation technologies.In late June 2025, the European Commission announced that it would impose provisional anti-dumping duties of 95.4% to 120.8% on imports into the European Union of choline chloride originating in the People's Republic of China, effective July 1, 2025. Mr. Harris said, “I was extremely pleased with the second quarter financial results. The Balchem team delivered record second quarter net sales, adjusted EBITDA, adjusted net earnings, and adjusted EPS while also delivering solid free cash flows.” Mr. Harris added, “Additionally, it was encouraging to see the European Commission’s provisional decision to impose signifi...

More updates from Balchem Corporation